The stock of Avinger Inc (NASDAQ:AVGR) is a huge mover today! The stock increased 6.24% or $0.28 during the last trading session, hitting $4.77. About 252,835 shares traded hands. Avinger Inc (NASDAQ:AVGR) has declined 72.01% since February 26, 2016 and is downtrending. It has underperformed by 82.43% the S&P500.
The move comes after 7 months positive chart setup for the $99.67 million company. It was reported on Sep, 30 by Barchart.com. We have $10.64 PT which if reached, will make NASDAQ:AVGR worth $122.59M more.
Analysts await Avinger Inc (NASDAQ:AVGR) to report earnings on November, 3. They expect $-1.04 EPS, up 3.70% or $0.04 from last year’s $-1.08 per share. After $-1.06 actual EPS reported by Avinger Inc for the previous quarter, Wall Street now forecasts -1.89% EPS growth.
According to Zacks Investment Research, “Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company’s product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City, California.”
More notable recent Avinger Inc (NASDAQ:AVGR) news were published by: Marketwatch.com which released: “Avinger Inc. NASDAQ: AVGR” on December 15, 2011, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” published on August 10, 2016, Finance.Yahoo.com published: “Avinger Inc. (AVGR) Lowers Guidance, Stock Down 40%” on July 13, 2016. More interesting news about Avinger Inc (NASDAQ:AVGR) were released by: Globenewswire.com and their article: “Avinger, Inc. Announces Closing of Public Offering of Common Stock and …” published on August 16, 2016 as well as Globenewswire.com‘s news article titled: “Avinger, Inc. Announces First Quarter 2016 Results” with publication date: May 04, 2016.
AVGR Company Profile
Avinger, Inc., incorporated on March 8, 2007, is a commercial-stage medical device company. The Firm designs, makes and sells image-guided, catheter systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Firm focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system. The Firm makes and sells a suite of products in the United States and select European markets. The Company’s products include Lightbox imaging console, as well as its Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.